Latest Definium Therapeutics News & Updates

See the latest news and media coverage for Definium Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Definium Therapeutics

Psychedelic medicine company for brain health disorders

definiumtx.com
Headquarters
New York, United States
Founded year
2019
Company type
Public company
Number of employees
150–200
Industry
Pharmaceuticals

Last updated

Latest news about Definium Therapeutics

In short: Definium Therapeutics reported positive Phase 3 results for DT120 in anxiety and depression and secured $805 million in public funding.

Company announcements

Definium Therapeutics

Definium Therapeutics receives FDA breakthrough therapy designation for DT120

The milestone follows positive Phase 3 trial results showing significant symptom improvement for major depressive disorder, marking the drug's second FDA breakthrough designation.

Unlock all announcements with a

Media coverage

HCP Live

The HCPFive: Top News for Healthcare Providers from the Week of 09/06 | HCPLive

On September 8, 2026, Definium Therapeutics received a second Breakthrough Therapy designation from the FDA for DT120 (lysergide) orally disintegrating tablet, this time for major...

Unlock all articles with a

Never miss news about Definium Therapeutics

Track Definium Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Definium Therapeutics competitors & trending companies

Browse news for competitors to Definium Therapeutics and other trending companies.